The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bostongene.com

Founded Year

2015

Stage

Series B | Alive

Total Raised

$200M

Valuation

$0000 

Last Raised

$150M | 2 mos ago

About BostonGene

BostonGene uses biomedical software for advanced patient analysis and personalized therapeutic decision-making in the fight against cancer. BostonGene's solution performs sophisticated analyses to assist physicians in evaluating viable treatment options for each patient's individual genetics, tumor microenvironment and tumor, clinical characteristics, and disease profile. BostonGene's seeks to enable physicians to provide all patients with the highest likelihood of survival through optimal cancer treatments using advanced and personalized therapies. The company was founded in 2015 and is based in Waltham, Massachusetts.

BostonGene Headquarter Location

University Office Park III 95 Sawyer Road, Suite 500

Waltham, Massachusetts, 02453,

United States

617-658-4545

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BostonGene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BostonGene is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,113 items

M

Medical Devices

8,079 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,800 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

BostonGene Patents

BostonGene has filed 32 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genomics
  • Bioinformatics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/12/2018

5/17/2022

Molecular biology, Oncology, Rotating disc computer storage media, Genomics, Biotechnology

Grant

Application Date

6/12/2018

Grant Date

5/17/2022

Title

Related Topics

Molecular biology, Oncology, Rotating disc computer storage media, Genomics, Biotechnology

Status

Grant

Latest BostonGene News

BostonGene Announces Integration With NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

May 10, 2022

The Inclusion of NCCN Guidelines® Into the BostonGene Tumor Portrait™ Test Report Allows Physicians Real-Time Access to Evidenced-Based Care for Cancer Patients May 10, 2022 09:10 AM Eastern Daylight Time WALTHAM, Mass.--( BUSINESS WIRE )--BostonGene today announced a strategic agreement with the National Comprehensive Cancer Network® (NCCN®) to integrate its Clinical Practice Guidelines into the BostonGene Tumor Portrait™ Test reports. The NCCN Guidelines® are comprehensive, evidence-based recommendations for the prevention, diagnosis, and management of cancer. Applicable to over 97% of malignancies affecting patients in the United States, the NCCN Guidelines assist physicians, nurses, payers, patients, and families in cancer care decision-making. The BostonGene Tumor Portrait™ Test uses DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing to analyze the tumor and its surrounding stroma, revealing critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response, and link findings to recommended management. By integrating genomic and transcriptomic analysis, in concert with the patient’s clinical history, the BostonGene Tumor Portrait™ Test provides information regarding biomarkers associated with response/resistance to therapies or therapeutic combinations, NCCN Guidelines treatment recommendations, and ongoing clinical trials. “Combining BostonGene's genomic and transcriptomic analysis with the NCCN Guidelines creates a significant opportunity to provide evidence-based care for cancer patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “We are pleased to be working with NCCN to further strengthen the BostonGene Tumor Portrait™ Test report and provide additional decision-making information to physicians.” “NCCN is committed to maintaining clinical practice guidelines that include actionable biomarkers and recommendations for cancer treatment options based upon biomarker results. We are pleased that BostonGene will be utilizing the NCCN Guidelines to generate reports linking biomarker results with evidence-based treatment recommendations,” said Robert W. Carlson, MD, Chief Executive Officer at NCCN. About BostonGene Corporation BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at  http://www.BostonGene.com . About NCCN The National Comprehensive Cancer Network® ( NCCN ®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ®) and other initiatives. Follow NCCN on Facebook @NCCNorg , Instagram @NCCNorg and Twitter @NCCN . Contacts

BostonGene Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BostonGene Rank

  • When was BostonGene founded?

    BostonGene was founded in 2015.

  • Where is BostonGene's headquarters?

    BostonGene's headquarters is located at University Office Park III, Waltham.

  • What is BostonGene's latest funding round?

    BostonGene's latest funding round is Series B.

  • How much did BostonGene raise?

    BostonGene raised a total of $200M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.